Prelude Therapeutics (PRLD) Stock: Buy, Sell, or Hold?
PRLD - Prelude Therapeutics Incorporated
$4.59
-0.08 (-1.71%)
▼
5d:
-12.57%
30d:
-19.9%
90d:
+11.68%
WAIT
LOW Confidence
Analysis Updated: Sep 11, 2026 12:00 AM ET
Earnings: Aug 13, 2026
0d
Get Alerted When PRLD Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: PRLD is down 12.6% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: PRLD is down 12.6% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: PRLD is currently trading at $4.59, which is considered oversold relative to its 30-day fair value range of $4.81 to $6.13. From a valuation perspective, the stock is trading at a discount (Forward PE: -6.1) compared to its historical average (34.9). At these levels, the market is pricing in 0% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, PRLD is in a uptrend. The price is currently testing key support at $4.56. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock scores a mixed 40/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $8.00 (+74.3%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, PRLD is in a uptrend. The price is currently testing key support at $4.56. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock scores a mixed 40/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $8.00 (+74.3%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$4.81 -
$6.13
Company Quality Score
49/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
84.3%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 74.3% below Wall St target ($8.00)
- BULLISH: Market expects only 0% annual growth - appears undervalued
- WARNING: Composite score 49/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$4.81 -
$6.13
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$4.56
Resistance Level
$6.38
Current Trend
Uptrend
Technical data as of
Sep 11, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-6.12
Wall Street Target
$8.00
(+74.3%)
Revenue Growth (YoY)
41.0%
Profit Margin
-269.8%
PE vs Historical
-6.1 vs 34.9
CHEAP
Share & Embed Analysis
Last updated: September 13, 2026 9:52 AM ET
Data refreshes hourly during market hours. Next update: 10:52 AM
Data refreshes hourly during market hours. Next update: 10:52 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is PRLD showing a specific setup today?
Insider Activity (6 Months)
2
Buys
0
Sells
+
Net
INSIDERS BUYING
Recent Transactions
David P Bonita
BUY
2815315 shares
2026-04-21
Orbimed Advisors Llc
BUY
2815315 shares
2026-04-21
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
INSM
Insmed Inc |
STRONG BUY
21 analysts |
$200 | 54 HOLD |
|
CRSP
Crispr Therapeutics AG |
BUY
28 analysts |
$88 | 44 HOLD |
|
CYTK
Cytokinetics Inc |
STRONG BUY
21 analysts |
$110 | 53 HOLD |
|
CRNX
Crinetics Pharmaceutical… |
STRONG BUY
17 analysts |
$86 | 46 HOLD |
|
BHVN
Biohaven Ltd. |
STRONG BUY
16 analysts |
$21 | 48 HOLD |
